Anthracycline-induced Heart Failure: Treatment and Recovery Prospects
https://doi.org/10.18087/cardio.2024.4.n2641
Abstract
The article presents a clinical case of heart failure associated with the anthracycline-containing antitumor therapy in a breast cancer patient with an initially low risk of developing cardiovascular complications.
Keywords
Heart failure,
breast cancer,
anthracycline-containing antitumor therapy,
cardiac toxicity,
left ventricular dysfunction
Supporting agencies: The work was supported by the Ministry of Health of Russia (clinical trial protocol #2018‑9‑1). No conflict of interest is reported.
About the Authors
M. V. Vitsenya
Chazov National Medical Research Center of Cardiology, Moscow
Russian Federation
Russian Federation
senior researcher at OALDT, Ph.D.
A. V. Potekhina
Chazov National Medical Research Center of Cardiology, Moscow
Russian Federation
Russian Federation
Senior Researcher, Department of Pulmonary Hypertension and Heart Diseases, ICC named after. A.L. Myasnikova, Ph.D.
A. Yu. Filatova
Chazov National Medical Research Center of Cardiology, Moscow
Russian Federation
Russian Federation
Researcher, Laboratory of Myocardial Fibrosis and HFpEF, OALDT, Ph.D.
O. V. Stukalova
Chazov National Medical Research Center of Cardiology, Moscow
Russian Federation
Russian Federation
senior researcher at the laboratory of MR tomography of the IKK im. A.L. Myasnikova, Ph.D.
F. T. Ageev
Chazov National Medical Research Center of Cardiology, Moscow
Russian Federation
Russian Federation
Head of the Department of Outpatient Treatment and Diagnostic Technologies, Doctor of Medical Sciences, Professor
References
1. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777
2. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology. 2010;55(3):213–20. DOI: 10.1016/j.jacc.2009.03.095
3. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 2017;35(8):893–911. DOI: 10.1200/JCO.2016.70.5400
4. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768–801. DOI: 10.1093/eurheartj/ehw211
5. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244
6. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083
7. Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardio-Oncology. 2020;6(1):24. DOI: 10.1186/s40959-020-00078-4
8. Martín-Garcia A, López-Fernández T, Mitroi C, Chaparro-Muñoz M, Moliner P, Martin-Garcia AC et al. Effectiveness of sacubitril–valsartan in cancer patients with heart failure. ESC Heart Failure. 2020;7(2):763–7. DOI: 10.1002/ehf2.12627
9. Vitsenya M.V., Potekhina A.V., Gavryushina S.V., Ibragimova N.M., Stukalova O.V., Masenko V.P. et al. Effects of sacubitril/valsartan in patients with cancer therapy-related heart failure. Therapeutic Archive. 2023;95(7):560–7. DOI: 10.26442/00403660.2023.07.202281
Supplementary files
|
1. видео 1 | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(30MB)
|
Indexing metadata ▾ | |
|
|
2. видео 2 | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(1MB)
|
Indexing metadata ▾ | |
|
|
3. видео 3 | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(43MB)
|
Indexing metadata ▾ | |
Review
For citations:
Vitsenya M.V., Potekhina A.V., Filatova A.Yu., Stukalova O.V., Ageev F.T. Anthracycline-induced Heart Failure: Treatment and Recovery Prospects. Kardiologiia. 2024;64(4):79-84. (In Russ.) https://doi.org/10.18087/cardio.2024.4.n2641
Views:
607
Email this article 
Post a Comment 
